denufosol Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Denufosol (INN) is an inhaled drug for the treatment of cystic fibrosis, being developed by Inspire Pharmaceuticals and sponsored by the Cystic Fibrosis Foundation. It was tested in two Phase III clinical trials, TIGER-1 and TIGER-2. Initially, in the first Phase III trial, TIGER-1, the compound showed significant results as compared with placebo. In the second Phase III trial, TIGER-2, the compound did not meet the primary endpoint, a significant change in baseline FEV1 at the week 48 endpoint as compared to placebo. As of 2011, no additional clinical studies are being conducted with the compound.   Wikipedia

Chemistry

  • SMILES: NC1=NC(=O)N(C=C1)[C@H]2C[C@H](O)[C@@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@H]([C@H](O)[C@@H]3O)N4C=CC(=O)NC4=O)O2
  • InChIKey: FPNPSEMJLALQSA-MIYUEGBISA-N
  • Mol. Mass: 773.32
  • ALogP: -2.87
  • ChEMBL Molecules:
    denufosol  
    denufosol tetrasodium  
More Chemistry

Pharmacology

Alternative names

denufosol | denufosol tetrasodium | ins37217 | ins 37217 | ins-37217 | p(1)-(uridine 5')-p(4)- (2'-deoxycytidine 5')tetraphosphate, tetrasodium salt

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Cystic Fibrosis (Phase 3)

Healthy Volunteers (Phase 1)

Macular Edema (Phase 2)

Retinal Detachment (Phase 2)

Rhinitis, Allergic, Perennial (Phase 2)

Uveitis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue